Serum MCP-1 and NGAL Play an Important Role in the Acute Inflammatory Event of Chronic Obstructive Pulmonary Disease

References

• Gardiner C, Gott M, Small N, et al. Living with advanced chronic obstructive pulmonary disease: patients concerns regarding death and dying. Palliat Med. 2009;23(8):691–697. DOI:10.1177/0269216309107003
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. DOI:10.1164/rccm.201204-0596PP
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. DOI:10.1016/S0140-6736(07)61382-8
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Brill SE, Allinson JP, et al. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181. DOI:10.1186/1741-7015-11-181
   PubMed Web of Science ®Google Scholar
• Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012; 106(8):1124–1133. DOI:10.1016/j.rmed.2012.04.008
   PubMed Web of Science ®Google Scholar
• Cheng Y, Lu Z, Tu X, et al. Community-acquired pneumonia and survival of critically ill acute exacerbation of COPD patients in respiratory intensive care units. COPD. 2016;11:1867–1872. DOI:10.2147/COPD.S113510
   Google Scholar
• Takir HB, Karakurt Z, Salturk C, et al. Reasons for ICU demand and long-term follow-up of a chronic obstructive pulmonary disease cohort. COPD. 2014;11(6):627–638. DOI:10.3109/15412555.2014.898041
   PubMedGoogle Scholar
• Park S, Lee SJ, Shin B, et al. The association of delta neutrophil index with the prognosis of acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med. 2020;20(1):47 DOI:10.1186/s12890-020-1083-4
   PubMed Web of Science ®Google Scholar
• Li H, Feng D, Cai Y, et al. Hepatocytes and neutrophils cooperatively suppress bacterial infection by differentially regulating lipocalin-2 and neutrophil extracellular traps. Hepatology. 2018;68(4):1604–1620. DOI:10.1002/hep.29919
   PubMed Web of Science ®Google Scholar
• Pain M, Bermudez O, Lacoste P, et al. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev. 2014;23(131):118–130. DOI:10.1183/09059180.00004413
   PubMedGoogle Scholar
• Xiao R, Chen R. Neutrophil gelatinase‑associated lipocalin as a potential novel biomarker for ventilator‑associated lung injury. Mol Med Rep. 2017;15(6):3535–3540. DOI:10.3892/mmr.2017.6442
   PubMed Web of Science ®Google Scholar
• Kuwabara T, Mori K, Mukoyama M, et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int. 2009;75(3):285–294. DOI:10.1038/ki.2008.499
   PubMed Web of Science ®Google Scholar
• Xu MJ, Feng D, Wu H, et al. Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology. 2015;61(2):692–702. DOI:10.1002/hep.27447
   PubMed Web of Science ®Google Scholar
• Xiao X, Yeoh BS, Vijay-Kumar M. Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr. 2017;37:103–130. DOI:10.1146/annurev-nutr-071816-064559
   PubMed Web of Science ®Google Scholar
• Wang Y, Jia M, Yan X, et al. Increased neutrophil gelatinase-associated lipocalin (NGAL) promotes airway remodelling in chronic obstructive pulmonary disease. Clin Sci. 2017;131(11):1147–1159. DOI:10.1042/CS20170096
   PubMed Web of Science ®Google Scholar
• Song Y-J, Zhou Z-H, Liu Y-K, et al. Prothrombotic state in senile patients with acute exacerbations of chronic obstructive pulmonary disease combined with respiratory failure. Exp Ther Med. 2013;5(4):1184–1188. DOI:10.3892/etm.2013.919
   PubMed Web of Science ®Google Scholar
• Shinke H, Masuda S, Togashi Y, et al. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol. 2015;76(5):989–996. DOI:10.1007/s00280-015-2880-y
   PubMed Web of Science ®Google Scholar
• Starrett W, Blake DJ. Sulforaphane inhibits de novo synthesis of IL-8 and MCP-1 in human epithelial cells generated by cigarette smoke extract. J Immunotoxicol. 2011;8(2):150–158. DOI:10.3109/1547691X.2011.558529
   PubMed Web of Science ®Google Scholar
• Monzon ME, Forteza RM, Casalino-Matsuda SM. MCP-1/CCR2B-dependent loop upregulates MUC5AC and MUC5B in human airway epithelium. Am J Physiol Lung Cell Mol Physiol. 2011;300(2):L204–215. DOI:10.1152/ajplung.00292.2010
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Coccini T, Roda E, et al. Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema. Int J Chron Obstruct Pulmon Dis. 2018;13:1691–1700. DOI:10.2147/COPD.S159915
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. 39930 03.00214-2017. DOI:10.1183/1
   PubMed Web of Science ®Google Scholar
• Gomez-Junyent J, Garcia-Vidal C, Viasus D, et al. Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PLoS One. 2014;9(8):e105854. DOI:10.1371/journal.pone.0105854
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Menendez R, Huerta A, et al. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest. 2013;143(4):1009–1017. DOI:10.1378/chest.12-1684
   PubMed Web of Science ®Google Scholar
• Gutierrez P, Closa D, Piner R, et al. Macrophage activation in exacerbated COPD with and without community-acquired pneumonia. Eur Respir J. 2010;36(2):285–291. DOI:10.1183/09031936.00118909
   PubMed Web of Science ®Google Scholar
• Huerta A, Crisafulli E, Menéndez R, et al. Pneumonic and Nonpneumonic Exacerbations of COPD: inflammatory response and clinical characteristics. Chest. 2013;144(4):1134–1142. DOI:10.1378/chest.13-0488
   PubMed Web of Science ®Google Scholar
• Almirall J, Bolibar I, Toran P, et al. Contribution of C-reactive nprotein to the diagnosis and assessment of severity of community- acquired pneumonia. Chest. 2004;125(4):1335–1342. DOI:10.1378/chest.125.4.1335
   PubMed Web of Science ®Google Scholar
• Yamauchi Y, Yasunaga H, Matsui H, et al. Comparison of clinical characteristics and outcomes between aspiration pneumonia and community-acquired pneumonia in patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:69. DOI:10.1186/s12890-015-0064-5
   PubMed Web of Science ®Google Scholar
• Aghasafari P, George U, Pidaparti R. A review of inflammatory mechanism in airway diseases. Inflamm Res. 2019;68(1):59–74. DOI:10.1007/s00011-018-1191-2
   PubMed Web of Science ®Google Scholar
• Boussekey N, Leroy O, Georges H, et al. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infect. 2005;33(4):257–263. DOI:10.1007/s15010-005-4096-2
   PubMed Web of Science ®Google Scholar
• Polzin A, Pletz M, Erbes R, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J. 2003;21(6):939–943. DOI:10.1183/09031936.03.00055103
   PubMed Web of Science ®Google Scholar
• Chung KF. The Role of Airway Smooth Muscle in the Pathogenesis of Airway Wall Remodeling in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc. 2005;2(4):347–354. DOI:10.1513/pats.200504-028SR
   PubMedGoogle Scholar